News & Media
News & Media

News & Media

The latest on Curie Therapeutics
Curie Therapeutics Recognized as a 2022 Prix Galien USA Nominee for Prix Galien Startup

CAMBRIDGE, Mass., August 17, 2022 – Curie Therapeutics Inc. (“Curie”), a biotechnology company focused on developing innovative radiopharmaceutical therapies for oncological diseases, today announced that The Galien Foundation, the premier global institution dedicated to honoring innovators in life sciences, named Curie a 2022 Prix Galien USA Award nominee for “Prix Galien Startup.” Winners will be…

Curie Therapeutics Appoints Georgette Verdin as Chief People Officer
Curie Therapeutics Appoints Karen Smith, M.D., Ph.D., as Independent Board Director
Curie Therapeutics Expands Radiopharmaceutical Expertise with Appointment of Bernard Lambert, Ph.D. as Chief Technology Officer
Curie Therapeutics Appoints Kapil Dhingra, MBBS, to Board of Directors
Curie Therapeutics Raises $75 Million Financing to Further its Mission of Transforming Cancer Care with Precision Radiopharmaceuticals

Contact Us

Curie Therapeutics Inc.
2F Gill Street
Woburn MA 01801

For Media:

For Investors: